Clinical Data Inc

Clinical Data — Investor Presentation (January 2009)

25 slides from Clinical Data's investor presentation, Jan 12, 2009

  1. Slide 1: January 12, 2009

    1 January 12, 2009

  2. Slide 2: Forward-Looking Statement

    Forward-Looking Statement 2 This presentation contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements a

  3. Slide 3: Investment Opportunity

    Investment Opportunity Clinical Data is a biotechnology company developing late-stage drugs that are first-in-class, best-in-category, or both. 3 High-margin products Product differentiation Lower technical risk Reduced development expense Intellectual property protection

  4. Slide 4: Disease Areas

    Disease Areas Central Nervous System Depression Pain (chronic and acute) Cardiovascular Disease Inherited cardiac conditions, e.g., Long QT Syndrome Stress test imaging Oncology Non-Hodgkin's lymphoma Breast cancer Colorectal cancer 4

  5. Slide 5: Current Value Drivers

    Current Value Drivers Two Phase III drugs: Vilazodone(tm): first-in-class & best-in-category antidepressant Stedivaze(tm): best-in-class cardiac stress imaging agent Deep pipeline of drug (Rx) and diagnostic (Dx) candidates Molecular diagnostic test revenue growing >100% year over year Specialized c

  6. Slide 6: 2009: A Year of Milestones

    2009: A Year of Milestones 6 Results from 2nd Phase III registration trial for Vilazodone End of Phase II meeting with FDA on Stedivaze Initiate Phase III program for Stedivaze Close of Avalon Pharmaceuticals acquisition 1H Vilazodone NDA filing IND filing for NME Publication of 1st Phase III regist

  7. Slide 7: Vilazodone for Major Depression

    Vilazodone for Major Depression First-in-class drug, dual mechanism of action SSRI 5HT1A Antidepressants are largest segment of U.S. CNS market $12+B annual sales; Global $20+B 200M prescriptions annually Largely undifferentiated products in increasingly 'generic' market Current drugs are limited Re

  8. Slide 8: Vilazodone: Blockbuster Potential

    Vilazodone: Blockbuster Potential Impressive results from first Phase III trial Statistically significant (P = .001) reduction in symptoms of depression Improvement in symptoms of depression in 1st week Generally well tolerated No difference in sexual dysfunction compared to placebo Proprietary biom

  9. Slide 9: Early Separation of Symptoms of Depression: Vilazodone vs. Placebo

    Early Separation of Symptoms of Depression: Vilazodone vs. Placebo - - ITT, LOCF - - P-values are for comparisons of vilazodone and placebo by ANCOVA Placebo (n=199) Vilazodone (n=198) 3.2 Baseline 1 2 3 4 5 6 7 8 Week of Treatment LSM Change from Baseline for MADRS p=0.0002 p=0.0127 p=0.0011 p=0.00

  10. Slide 10: Patients with Proprietary Biomarker Demonstrate Substantial Decrease in Symptoms of Depression

    Patients with Proprietary Biomarker Demonstrate Substantial Decrease in Symptoms of Depression Mean MADRS +/- SEM 1 2 3 4 5 6 7 8 0 5 15 25 35 Placebo with biomarker Placebo without biomarker Vilazodone without biomarker Biomarker patients had 2X response at week 8 30% of patients are biomarker posi

  11. Slide 11: Most Common Adverse Events

    Zoloft(r) (sertraline hydrochloride)* Zoloft(r) (sertraline hydrochloride)* Zoloft(r) (sertraline hydrochloride)* AE Drug Placebo Nausea 26% 12% Diarrhea/ loose stools 18% 9% Somnolence 13% 6% Tremor 11% 3% Sweating Increased 8% 3% Ejaculation failure 7% <1% Dyspepsia 6% 3% Most Common Adverse Event

  12. Slide 12: Vilazodone Development Milestones

    Vilazodone Development Milestones Second Phase III registration trial began March 2008 Enrollment completed 7 weeks ahead of schedule Data expected Q2 2009 Long-term safety study fully enrolled Target 600 patients on drug for 12 months; currently ~300 patients have been on drug for 6+ months Commerc

  13. Slide 13: Stedivaze: Cardiac Stress Agent

    Stedivaze: Cardiac Stress Agent Stedivaze: Cardiac Stress Agent Best-in-class Rx used as Dx stress agent U.S. market projected to be $800M in 20111 Ex-U.S. marketing collaboration discussions underway Additive to cardiovascular focus, specialty sales force Phase II data demonstrated: Improved tolera

  14. Slide 14: Phase II Results: Stedivaze AE Profile is Better than Adenoscan

    Phase II Results: Stedivaze AE Profile is Better than Adenoscan Hendel et al AHA, 2005 *Safety population only. Incidence of AEs 5% or greater. 14 Dyspnea Chest Pain Dizziness Headache Flushing Hypotension Nausea 2° AV Block 0 20 40 Stedivaze (Apadenoson) 1.0 ^g/kg 2.0 ^g/kg Adenoscan % Change from

  15. Slide 15: Stedivaze Development Milestones

    Stedivaze Development Milestones Successful end-of-Phase II meeting with FDA in Jan. 2009 Consensus on overall trial design and use of fixed dose regimen Clarified extent of other common program requirements to be considered for the NDA submission Initiate Phase III program in 1H 2009, as scheduled

  16. Slide 16: Our Therapeutics Pipeline

    Our Therapeutics Pipeline Current Stage Lead Discovery Preclinical Phase I Phase II Phase III NDA Marketed Novartis Confidential Partner Vilazadone(tm) Stedivaze(tm) Cardiac Imaging ATL1222: Acute Inflammation ATL844: Diabetes / Asthma ATL313 : Ophthalmic Pain Other indications Projected Stage In 12

  17. Slide 17: Acquisition of Avalon Pharmaceuticals (AVRX)

    Acquisition of Avalon Pharmaceuticals (AVRX) Expands capabilities in oncology Rx and Dx Drug discovery platform to identify biomarkers and targets Partnered programs with Merck and Novartis Proposed acquisition announced 10/28/08 $10M all-stock transaction subject to AVRX shareholder approval; antic

  18. Slide 18: FAMILION: Dx for Inherited Cardiac Conditions

    FAMILION(r): Dx for Inherited Cardiac Conditions Genetic tests to detect mutations associated with inherited cardiac syndromes Tests are used to: Diagnose disease Guide treatment decisions Determine risk in family members ACC/AHA/ESC guidelines recommend genetic testing for suspected carriers 18

  19. Slide 19: Family of Genetic Tests

    (1) Prevalence & incidence rates exclude International markets. Sources: Selected industry and academic publications and resources. Test Long Q/T ~100,000 1/3,000 Incidence/ Prevalence U.S. Disease Unknown (1) ~500,000 1/500 Hypertrophic Cardiomyopathy Brugada Syndrome ~28,000 1/10,000 Catecholamine

  20. Slide 20: FAMILION: Over 100% Growth Year Over Year

    FAMILION: Over 100% Growth Year Over Year* Up over 100M covered lives since Jan. 2008 20 FAMILION: Over 100% Growth Year Over Year $0 $500,000 $1,000,000 $1,500,000 $2,000,000 $2,500,000 2004 2005 2006 2007 2Q 2008 New Sales Force *Calendar Year

  21. Slide 21: Next Steps for FAMILION

    Next Steps for FAMILION Continue to increase payor coverage Leverage cardiac sales force with additional products Partnerships to expand distribution ex-U.S. United Kingdom Ireland Australia/New Zealand Other EU countries 21

  22. Slide 22: Dx for Drug Response: PGxPredict Tests

    Dx for Drug Response: PGxPredict(r) Tests Build body of data to establish role for FCGR3A testing in NHL, breast cancer, colon cancer and RA 22 Predict drug response, Inform treatment decisions Oncology CNS RA Diabetes In Development Commercially Available

  23. Slide 23: Clinical Data Profile

    Clinical Data Profile* Ticker: CLDA Market Cap: $194.22M Shares Outstanding: 22.74M Revenue: $18.0M for 1H 2008 Cash: $52.1M at Sept. 30, 2008 Debt: $29.1M at Sept. 30, 2008 Insider Ownership: 52% Substantially all shares were purchased 23 * As of 1/2/09 unless otherwise indicated

  24. Slide 24: Business Model: Integrated & Reproducible

    High-margin products Product differentiation Lower technical risk Reduced development expense Intellectual property protection Business Model: Integrated & Reproducible 24 Biomarker IP & Expertise Rx + Dx Product Franchises Vilazodone Companion Dx Payor Oriented Patient/Provider Patient/Provider

  25. Slide 25: Thank you

    25 Thank you

Clinical Data — Investor Presentation (January 2009) on 6ix